Atopic Dermatitis Highlights

CE / CME

Research Highlights on Atopic Dermatitis: Practice-Changing Results From Recent Clinical Trials

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: November 05, 2020

Expiration: November 04, 2021

Pretest

Progress
1 2
Course Completed
1.

Patient Case 1

WL is a 46-yr-old male with Crohn’s disease

He presents today with increasing abdominal cramps and pain and fatigue

  • Current therapy: IFX 5 mg/kg IV every 8 wks

What are the next steps according to AGA recommendations regarding reactive TDM?

2.
Which TDM strategy for biologics is most often used in patients with active disease?
3.

Patient Case 2

AC is a 38-yr-old female with ulcerative colitis remission

She presents at her annual visit with no complaints and feels well

  • Current therapy: IFX 10 mg/kg IV every 4 wk
  • Maintenance IFX level: 49 µg/mL with no antibodies

According to Papamichael and colleagues, the following recommendations regarding proactive TDM would apply to this patient:

4.
Which of the following is a recommendation by the AGA moderate to severe luminal Crohn disease 2021 guidelines?
5.
Which emerging agent had greater clinical remission at Wk 8 (induction) compared with placebo?
6.
Which of the following is part of the buyer's responsibilities?
7.
Which pharmacist recommendation may decrease the risk of poor outcomes in CD, such as loss of response to biologic therapy?